Conclusions
Uncontrolled plasma HIV RNA was independently associated with a higher likelihood of developing AIDS-defining malignancies, while immunosuppression was associated with a higher risk of developing any types of malignancies. Antiretroviral treatment should aim at reaching and maintaining a CD4 count >500/mm to prevent the occurrence of malignancy, this should be integrated to
Introduction
The association between HIV infection and the occurrence of certain types of malignancies has been established for a long time .
[1 ]
Due to their high incidence rates among HIV-infected patients, Kaposi s sarcoma (KS), non-Hodgkin s lymphoma (NHL) and invasive ' ' cervical cancer are considered as AIDS-defining malignancies . Their high incidence may be explained by cellular immunosuppression [2 ] and chronic infection with oncogenic viruses , . Since 1996, the substantial improvement in survival after HIV infection related to the [1 3 ] increasing use of combination antiretroviral therapy (cART) has been associated with changes in the spectrum of HIV morbidity and mortality . Indeed, the incidence of non-AIDS-defining malignancies among people living with HIV is two to three times higher than [4 -6 ] within the general population and malignancies, whether AIDS-defining or not, have become the most frequent cause of death in HIV-infected patients . Such an increase in the proportion of deaths due to malignancies may be explained by prolonged survival, [6 -8 ] overall ageing of the HIV-infected population and a decreasing mortality related to opportunistic infections . The high prevalence [9 -13 ] of traditional risk factors for malignancies, such as tobacco or alcohol consumption, infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) will act as contributing factors . In addition, the role of HIV related immunosuppression as a specific risk factor for [14 -16 ] non-AIDS-defining malignancies is strongly suspected, and a relationship between the risk of hepatocarcinoma and HIV related immunosuppression was recently shown . Furthermore, a direct role of HIV in the occurrence of malignancies is suggested .
[17 ] [18 -22 ] Finally, as exposure to immunodeficiency or uncontrolled plasma HIV RNA viral load can be considered as cumulative over the time or current, it remains unclear which type of exposure should be considered in assessing the risk of malignancy. Our objective was to investigate the association between the occurrence of a first malignancy in HIV-infected patients and the immuno-virological characteristics observed over time in a large cohort of HIV-infected patients in care, in which malignancies are prospectively recorded.
Methods

Study population
Data collected between January 1 , 1998 and December 31 , 2006 within the ANRS CO3 Aquitaine Cohort, a prospective st st hospital-based cohort of HIV-1-infected patients under routine clinical management, in South-Western France, were used . This cohort [23 ] was initiated in 1987 at the Bordeaux University hospital and in four other public hospitals by the Groupe d Epid miologie Clinique du
Sida en Aquitaine (GECSA). All adults who are in-or out-patients of the participating hospital wards, with HIV-1 infection confirmed by
Western blot testing and having given informed consent, are eligible in the cohort. Patients included in this analysis had (i) at least three months of follow-up, (ii) at least two visits reported during the study period and (iii) at least one plasma HIV RNA and CD4 cell count + measurements documented during the study period. All morbid events are collected using the International Classification of Diseases 10 th revision codes. The codes corresponding to malignancies were extracted from the database to identify the cases. Malignancies diagnosed before January 1 , 1998, or during the first three months of follow-up in the Aquitaine Cohort were considered as prevalent cases and st were not included in this study.
Risk factors and outcomes
The primary outcome was a confirmed diagnosis of a first malignancy during the follow-up period. All cases were validated through histological reports or source medical files documenting the diagnosis. The following time-updated variables were considered: time spent with a CD4 cell count less than two pre-defined thresholds; latest available CD4 cell count; time spent with plasma HIV RNA above + + two pre-defined thresholds; latest available plasma HIV RNA measurement; duration of cART exposure and latest cART prescription. We considered 200 CD4 /mm as a marker of severe immunosuppression and 500 CD4 /mm as a marker of immune restoration . We
used 500 copies/mL as the lowest threshold of plasma HIV RNA that could be detected throughout the 10-year study period. We also considered the threshold of 10,000 copies/mL as a high level of HIV replication. To estimate the time spent with plasma HIV RNA above the defined thresholds, we assumed that the value of the measurement reported at a given follow-up visit remained stable until the next follow-up visit. We made the same assumptions to estimate the time spent in each CD4 cell count category and the duration of cART + exposure. When plasma HIV RNA or CD4 cell count value was missing at a recorded follow-up clinic visit, it was estimated using the + last observation carried forward method. Missing values were counted as such when the delay between the last available value and the missing one was >6 months. cART was defined as a regimen including at least three antiretroviral drugs.
Statistical analysis
Proportional hazards regression models with delayed entry were used to estimate the association between time-updated variables, gender, and the risk of occurrence of a first new diagnosis of malignancy for a given patient during the study period. Age was the baseline time as, in such a Cox model, we assume that the risk of malignancy is strongly age dependent. However, this introduces a left truncation problem and we considered a delayed entry at the date of the follow-up visit reporting the first plasma HIV RNA after January 1 , 1998. The main analyses considered separately AIDS-defining malignancies and non-AIDS-defining malignancies, while robustness analyses considered KS and NHL.
In the models taking into account the latest measurement, plasma HIV RNA and CD4 cell count were considered as binary variables + (higher or lower than the threshold considered), and cART was considered as prescribed or not. All adjusted models considered the following variables: CD4 cell count lower than the threshold pre-specified in the model (duration of exposure or latest measurement), usually occurs after a long exposure to potential determinants and current values might be a consequence rather than a cause of malignancy. Both types of summary statistics are studied in separate models since they are highly correlated. The models were compared with the Akaike criterion (AIC), the lower the better fit.
In all analyses, patients affected by a malignancy that was not included in the outcome definition were right-censored at the time of the diagnosis. This means that the follow-up of patients affected by an AIDS-defining malignancy was right-censored while the hazard of non-AIDS-defining malignancies was estimated. As a history of malignancy was an exclusion criterion, no prevalent cases were included.
Due to incomplete data regarding traditional risk factors for non-AIDS malignancies (tobacco consumption, HBV and HCV infections), they were not considered in the analyses performed on the entire dataset. Hence, a robustness analysis adjusted for these risk factors, considering them as fixed-effect variables, was conducted on patients with available data concerning tobacco consumption, HBV and HCV infections. SAS software (version 9.1, SAS Institute, Cary, NC) was used to perform the analyses.
®
Results
During the study period 4,828 patients were followed-up in the ANRS CO3 Aquitaine Cohort, 324 of them had a diagnosis of malignancy at study entry and were excluded from the analyses. In addition, 310 patients did not meet the study inclusion criteria. Thus, among 4,194 eligible patients, accounting for 22,389 person-years (py), 251 first new diagnosis of malignancy were validated through histological (111 cases) or medical reports (140 cases). The cohort was predominantly male (72 ), the 144 non-AIDS-defining % malignancies and the 107 AIDS-defining malignancies were experienced by 83 and 78 men. The incidence rates of AIDS-defining shows the distribution of malignancies and the characteristics of these patients.
% - Table 1 Among the 97,893 follow-up visits recorded during the study period, 5,033 concerned patients affected by a malignancy. At least two plasma HIV RNA and CD4 measuremens were reported among 4,145 patients (240 malignancies) and 4,155 patients (241 malignancies), respectively.
AIDS-defining malignancies
Both CD4 <200 cells/mm and plasma HIV RNA viral load >500 copies/mL were strongly and independently associated with a
higher risk of AIDS-defining malignancy, whatever the type of exposure considered (cumulative or current: ). Each additional year  table 2 of exposure to cART was associated with a lower risk of AIDS-defining malignancy, while current exposure to cART and gender were not related to the hazard of AIDS-defining malignancy ( ) .  table 2 Sixty-one cases of NHL were diagnosed over the study period among the 4,194 patients included, accounting for 57 of all diagnoses % of AIDS-defining malignancies. Current exposure to both plasma HIV RNA viral load >500 copies/mL and CD4 <200 cells/mm was 
Non-AIDS-defining malignancies
A CD4 cell count <500 cells/mm was independently associated with a higher hazard of non-AIDS-defining malignancy, whatever table 3 whatever the model considered, while female gender was related to a lower hazard ( ). Analyses using higher thresholds for plasma  table 3 HIV RNA and considering the cumulative exposure led to similar results (data not shown). In analyses considering lower thresholds for CD4 cell count, each year spent with CD4 <200 cells/mm was independently associated with a higher risk of non-AIDS-defining 
Adjustment for other risk factors of malignancy
Among 3,210 patients with available data regarding tobacco consumption and HBV or HCV co-infection status, 113 non-AIDS-defining malignancies occurred.
The thresholds considered were 500 copies/mL for plasma HIV RNA and 500 cells/mm for CD4 . The results of these analyses 
Comparison between cumulative and current exposure
The difference in AIC between the model taking into account the current exposure to latest measurement compared to the model considering the cumulative exposure ( and ) could be considered as negligible in each instance . tables 2 3
[27 ]
Discussion
Immunodeficiency is known to be associated with a higher hazard of AIDS-defining malignancy and our results are in accordance with this body of knowledge. Moreover, our study shows that HIV replication, as both current and cumulative exposure to uncontrolled plasma HIV RNA viral load were associated with a higher hazard AIDS-defining malignancy, has a major impact on the risk of occurrence of AIDS-defining malignancies, particularly NHL. This suggests that the control of plasma HIV RNA is a key factor to prevent NHL occurrence, at all stages of immune deficiency. HIV replication, through activation of the immune system, could be independently involved in the occurrence of NHL in patients with high CD4 cell counts . The fact that exposure to cART was only associated with a + [28 ] lower risk of AIDS-defining malignancy needs to be further explored. However, it is difficult to disentangle the proper effect of cART, immune deficiency and viral replication and one may speculate that the absence of significant association between cART exposure and non-AIDS-defining malignancy is linked to the absence of association with HIV replication. Thus, the potential benefit of cART for controlling non-AIDS-defining malignancy might be due to immune reconstitution rather than control of viral replication per se. In other hand, both longer and current exposure to uncontrolled plasma HIV RNA and immunosuppression were associated with a higher risk of AIDS-defining malignancy, underlining that the best possible control of HIV infection is warranted to prevent AIDS-defining malignancies and especially NHL occurrence.
Several cohort studies have shown a higher risk of non-AIDS-defining malignancy in HIV-infected patients when compared with the general population but none of them considered the duration of exposure to immunodeficiency , , , . Another large study failed [9 11 12 29 ] to show any relationship between immunodeficiency at AIDS diagnosis and the risk of malignancy . Our results are consistent with a [30 ] higher incidence of non-AIDS-defining malignancies observed in solid organ transplant recipients, chronically exposed to immunosuppressive therapy, indirectly suggesting that immunodeficiency is independently associated with a higher risk of non-AIDS-defining malignancies in HIV-infected patients , . Furthermore, our results regarding the latest CD4 cell count showed [31 32 ] + that current immunodeficiency may be involved in the risk of malignancy. This suggests that, following a prescription of cART, the risk of malignancy may decrease when the CD4 cell count rises above 500 cells/mm . Our results regarding cumulative exposure to CD4 <500 provides a stronger argument that HIV infected patients may benefit from early initiation of antiretroviral treatment to decrease the risk of AIDS and non-AIDS-defining malignancies.
Burgi et al found that the use of cART was protective for malignancies, and the D:A:D cohort collaboration found that the [33 ] incidence of fatal non-AIDS malignancies was related to exposure to cART . Our main objective was not to estimate the independent [34 ] effect of cART exposure on the risk of malignancy, and further studies including more patients should specifically address this issue.
However, our results show that early control of HIV replication and maintenance of high levels of CD4 cell count are associated with + lower risk of malignancies.
Malignancy, HIV and immune deficiency
Clin Infect Dis . Author manuscript Page / 5 8 The incidence rate of non-AIDS-defining malignancies was higher in men than in women, as it is commonly observed in the general population in France . [35 ] Due to incomplete data regarding the risk factors for non-AIDS-defining malignancies (tobacco consumption, HBV or HCV infections), we could not take these risk factors into account in the analyses of the entire cohort. However, these confounding factors were controlled for in analyses estimating the risk of non-AIDS-defining malignancy in a large subgroup of patients free of missing values concerning these data. The association between immunosuppression and the occurrence of specific non-AIDS-defining malignancies could not be explored in this study. We acknowledge that larger number of cases is needed to reach larger statistical power to adequately address this issue for each type of non-AIDS-defining malignancy.
Finally, our study showed that exposure to uncontrolled plasma HIV-RNA was associated with a higher risk of AIDS-defining malignancy, regardless of CD4 cell count and the use of cART. Furthermore, immunodeficiency was associated with a higher risk of + malignancy, whether AIDS-defining or not. Considering the global ageing of the HIV-infected population in developed countries, malignancy, which is already one of the main causes of mortality, is likely to become the first clinical and public health challenge in the long-term management of HIV-infected patients.
According to our observations, the objective of cART should aim at reaching and maintaining not only an undetectable plasma HIV RNA, but also a CD4 cell count higher than 500 cells/mm to prevent the occurrence of malignancy, AIDS-defining or not. In HIV
infected population, this should be integrated to malignancy prevention policies.
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